MDNA.TO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 22:49):

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases...

Stats
Dzisiejszy wolumen	75 944.00
Średni wolumen	179 400
Kapitalizacja rynkowa	166.43M
EPS	$0 ( 2024-02-15 )
Następna data zysków	( $-0.0600 ) 2024-06-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.39
ATR14	$0.0170 (0.71%)

MEDICENNA THERAPEUTICS Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MEDICENNA THERAPEUTICS Korelacja - Waluta/Towar

0.51
( weak )

0.63
( weak )

0.00
( neutral )

0.50
( neutral )

0.34
( neutral )

0.03
( neutral )

MEDICENNA THERAPEUTICS Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$-5 000.00 (0.00 %)
EPS:	$0.0239

FY	2022
Przychody:	$0
Zysk brutto:	$-5 000.00 (0.00 %)
EPS:	$0.0239

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.420

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.350

Financial Reports:

No articles found.

MEDICENNA THERAPEUTICS

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.